NCT00279019 - Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2005

Primary Completion Date

June 13, 2006

Study Completion Date

June 13, 2006

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK233705

GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.

DRUG

Tiotropium

Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.

DRUG

Placebo

Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose

Trial Locations (3)

14050

GSK Investigational Site, Berlin

22927

GSK Investigational Site, Großhansdorf

30625

GSK Investigational Site, Hanover